Compare MP & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | CYTK |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | MP | CYTK |
|---|---|---|
| Price | $68.80 | $62.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $70.92 | ★ $82.38 |
| AVG Volume (30 Days) | ★ 7.8M | 2.2M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $232,742,000.00 | $87,211,000.00 |
| Revenue This Year | $34.68 | $339.72 |
| Revenue Next Year | $137.40 | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 26.44 | ★ 2609.26 |
| 52 Week Low | $18.64 | $29.31 |
| 52 Week High | $100.25 | $70.98 |
| Indicator | MP | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 47.75 |
| Support Level | $62.20 | $60.30 |
| Resistance Level | $70.07 | $65.08 |
| Average True Range (ATR) | 3.73 | 2.91 |
| MACD | 1.58 | -0.01 |
| Stochastic Oscillator | 94.24 | 45.74 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.